Allarity Therapeutics Inc. reported a cash position of $16.9 million as of September 30, 2025, a decrease of $0.9 million from June 30, 2025. Research and development expenses for the third quarter of 2025 were $1.2 million, up from $1.0 million in the same period in 2024. General and administrative expenses were $1.3 million, down from $1.6 million in the third quarter of 2024. The net loss attributable to common stockholders was $2.8 million, compared to a net loss of $12.2 million in the third quarter of 2024. Key business developments included receiving FDA Fast Track designation for stenoparib in advanced ovarian cancer, reporting median overall survival now exceeding 25 months in an ongoing Phase 2 trial, and signing a new commercial agreement to license breast cancer DRP algorithms and laboratory services. The company maintains a financial runway through the fourth quarter of 2026.